Analyzing Genelux (GNLX) and Its Peers

Genelux (NASDAQ:GNLXGet Free Report) is one of 959 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Genelux to related businesses based on the strength of its dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Risk & Volatility

Genelux has a beta of -1.18, meaning that its stock price is 218% less volatile than the S&P 500. Comparatively, Genelux’s peers have a beta of 1.10, meaning that their average stock price is 10% more volatile than the S&P 500.

Valuation and Earnings

This table compares Genelux and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Genelux $170,000.00 -$28.30 million -4.74
Genelux Competitors $1.65 billion $150.62 million -1.84

Genelux’s peers have higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

37.3% of Genelux shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 11.7% of Genelux shares are held by insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Genelux and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genelux N/A -125.58% -86.03%
Genelux Competitors -3,062.12% -293.82% -34.22%

Analyst Ratings

This is a summary of current recommendations and price targets for Genelux and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux 0 0 4 0 3.00
Genelux Competitors 6390 18218 43658 911 2.57

Genelux currently has a consensus price target of $34.00, suggesting a potential upside of 639.13%. As a group, “Pharmaceutical preparations” companies have a potential upside of 76.45%. Given Genelux’s stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than its peers.


Genelux peers beat Genelux on 8 of the 13 factors compared.

About Genelux

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with's FREE daily email newsletter.